BRIEF-Eni Signs Deal With GIP For Potential Sale Of A Co-Control Stake In Eni CCUS Holding-February 2024-www.financetom.com

BRIEF-Eni Signs Deal With GIP For Potential Sale Of A Co-Control Stake In Eni CCUS Holding

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Eni Signs Deal With GIP For Potential Sale Of A Co-Control Stake In Eni CCUS Holding

May 27, 2025 4:45 AM

May 27 (Reuters) - Eni SpA ( E ):

* EXCLUSIVITY AGREEMENT SIGNED WITH GIP FOR THE POTENTIAL

SALE OF

A CO-CONTROL STAKE IN ENI CCUS HOLDING

* COMPLETES DRAFTING OF DOCUMENTS RELATED TO THE SALE OF A

CO-CONTROL STAKE OF 49.99% IN ENI CCUS HOLDING

* GIP WILL SUPPORT INVESTMENTS IN THE CCUS PROJECTS

Further company coverage:

(Gdansk Newsroom)

Previous page： Why Is 3D Printing Company Stratasys Stock Surging Today? Next page： Jazz Pharmaceuticals Says Gastric Cancer Therapy Shows Promise in Mid-Stage Study

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Why Is 3D Printing Company Stratasys Stock Surging Today?

Sep 16, 2024

Stratasys, Ltd. ( SSYS ) shares are trading higher premarket Monday after the company approved a $50 million share repurchase program. The repurchase program is part of Stratasys’ strategy to enhance shareholder value and follows its restructuring plan, which aims to save $40 million annually starting in the first quarter of 2025. The plan included a 15% workforce reduction by...

Jazz Pharmaceuticals Says Gastric Cancer Therapy Shows Promise in Mid-Stage Study

Sep 16, 2024

08:54 AM EDT, 09/16/2024 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said Monday that updated data from the mid-stage study of its experimental therapy, zanidatamab, combined with chemotherapy for HER2-positive advanced or metastatic gastroesophageal adenocarcinoma were positive. Data showed that among 41 patients treated with zanidatamab in combination with chemotherapy, the median progression-free survival was 15.2 months, and the...

Carl Icahn welcomes dismissal of Icahn Enterprises lawsuit, not selling shares

Sep 16, 2024

(Reuters) - Carl Icahn said on Monday he was pleased a federal judge dismissed a lawsuit accusing the billionaire of defrauding shareholders of his investment company Icahn Enterprises ( IEP ) so he could obtain large amounts of personal loans. The lawsuit followed a May 2023 report by the short-selling firm Hindenburg Research that questioned whether Icahn's company inflated its...

Kyverna Therapeutics Names Warner Biddle CEO

Sep 16, 2024

09:01 AM EDT, 09/16/2024 (MT Newswires) -- Kyverna Therapeutics ( KYTX ) said Monday that it has appointed Warner Biddle to succeed Peter Maag as chief executive officer, effective immediately. Biddle previously served as senior vice president and global head of commercial for Kite Pharma, a Gilead (GILD) company. Price: 7.44, Change: +0.24, Percent Change: +3.33 ...